Skip to main content
. 2023 Jul 15;56(4):518–528. doi: 10.1007/s11239-023-02859-x

Table 2.

Incidence rates and hazard ratios of outcomes after inverse probability of treatment weighting

Outcome DOACs group (n = 503) Warfarin group (n = 508) Adjusted
HR (95% CI)b
Events PY Rate (95%CI)a Events PY Rate (95%CI)a
Stroke/SE 5 208 2.25 (0.91–5.56) 17 259 6.54 (4.06–10.53) 0.29 (0.09–0.97)
Major bleeding 9 208 4.33 (2.25–8.33) 7 257 2.74 (1.31–5.74) 0.99 (0.34–2.92)
Any ischemia 17 202 8.27 (5.12–13.34) 35 248 14.18 (10.18–19.74) 0.42 (0.22–0.79)
Any bleeding 55 194 28.38 (21.80-36.95) 65 202 32.31 (25.33–41.20) 0.74 (0.50–1.09)

a Incidence rate, per 100 person-years

b Weighted with inverse probability of treatment weighting (IPTW) and adjusted for age, sex, chronic obstructive pulmonary disease, gastrointestinal ulcer, diuretics, antidiabetics, CHA2DS2-VASc score, HAS-BLED score, smoking status, prior bleeding, cerebrovascular disease, myocardial infarction, peripheral vascular disease, venous thromboembolism, antiplatelets, non-steroidal anti-inflammatory drugs

Abbreviations: DOACs, direct oral anticoagulants; PY person-years; SE systemic embolism

HHS Vulnerability Disclosure